Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Acyclic Hydrocarbon α,ω-Dienes: From Biomass and Plastic Upcycling to Carbocycles, Precision Polymers, and Cross-Linked Elastomers.

ChemSusChem·2026

Same author

Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic Developments.

Cancers·2026

Same author

Case Report: Long-term response to multimodal treatment in metastatic uveal melanoma.

Frontiers in immunology·2026

Same author

The Spectrum of Venetoclax-Based Treatments in Acute Myeloid Leukemia.

Cancers·2026

Same author

Curative Approach to the Treatment of Beta-Thalassemia and Sickle Cell Disease with Hematopoietic Stem Cell Transplantation.

Journal of clinical medicine·2026

Same author

Gene Therapy of Beta Hemoglobinopathies.

Biomedicines·2025

Search research articles

Related Experiment Video

Updated: Jul 1, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

CAR-T Cell Therapy for T-Cell Malignancies.

Ugo Testa¹, Patrizia Chiusolo^2,3, Elvira Pelosi¹

¹Istituto Superiore di Sanità, Roma, Italy.

Mediterranean Journal of Hematology and Infectious Diseases

|March 12, 2024

Summary

Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for T-cell malignancies. Despite challenges like fratricide and tumor contamination, advancements in CD7 and CD5 targeting are improving outcomes.

Keywords:

Adults T cell acute lymphoblastic leukemia CAR-T Cells T-cell lymphoblastic lymphoma

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Related Experiment Videos

Last Updated: Jul 1, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Area of Science:

Oncology
Immunotherapy
Cellular Therapy

Background:

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed B-cell lymphoid neoplasia treatment, leading to six FDA-approved products.
This success has spurred research into CAR-T for other hematologic tumors, including T-cell malignancies.

Purpose of the Study:

To explore the application and limitations of CAR-T cell therapy in T-cell malignancies.
To highlight recent progress in targeting CD7 and CD5 for T-cell cancer treatment.

Main Methods:

Review of current CAR-T cell therapy approaches for hematologic tumors.
Analysis of challenges specific to T-cell malignancies, including antigen sharing and tumor contamination.
Examination of strategies to overcome limitations, such as allogeneic CAR-T products.

Main Results:

CAR-T therapy success in T-cell neoplasms is limited by fratricide due to shared antigens and malignant T-cell contamination.
Allogeneic CAR-T products mitigate contamination but introduce immunological incompatibility issues.
Significant progress has been made in CD7- and CD5-targeted CAR-T therapies for T-cell malignancies.

Conclusions:

CAR-T cell therapy faces unique hurdles in treating T-cell malignancies.
Ongoing research and development in targeted CAR-T strategies are crucial for improving patient outcomes.